C

Curative Biotechnology Inc
OTC:CUBT

Watchlist Manager
Curative Biotechnology Inc
OTC:CUBT
Watchlist
Price: 0.0043 USD -12.24%
Market Cap: 4.6m USD

Curative Biotechnology Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Curative Biotechnology Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
C
Curative Biotechnology Inc
OTC:CUBT
Net Income (Common)
-$18.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Net Income (Common)
$43.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Incyte Corp
NASDAQ:INCY
Net Income (Common)
$1.2B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Medpace Holdings Inc
NASDAQ:MEDP
Net Income (Common)
$433m
CAGR 3-Years
24%
CAGR 5-Years
28%
CAGR 10-Years
N/A
United Therapeutics Corp
NASDAQ:UTHR
Net Income (Common)
$1.3B
CAGR 3-Years
22%
CAGR 5-Years
22%
CAGR 10-Years
7%
No Stocks Found

Curative Biotechnology Inc
Glance View

Market Cap
4.6m USD
Industry
N/A

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. The company is headquartered in Boca Raton, Florida. The company went IPO on 2001-07-11. The firm is focused on identifying, acquiring and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech has ongoing programs in three different therapeutic areas: infectious disease, neuro oncology and degenerative eye disease. The firm's pipeline includes IMT504, CURB906 and Metformin Reformulation. IMT504 is a immune therapy to treat rabies. CURB906 is a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. Metformin Reformulation to treat degenerative eye disease.

CUBT Intrinsic Value
Not Available
C

See Also

What is Curative Biotechnology Inc's Net Income (Common)?
Net Income (Common)
-18.8m USD

Based on the financial report for Dec 31, 2021, Curative Biotechnology Inc's Net Income (Common) amounts to -18.8m USD.

What is Curative Biotechnology Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
-303%

Over the last year, the Net Income (Common) growth was -303%.

Back to Top